Annexon Inc Annual Shareholders Meeting Transcript
Good morning. I am Douglas Love, President and CEO of Annexon. I'm very happy to welcome you to Annexon's 2022 Annual Meeting of Shareholders.
2021 was a marked -- was a year of marked progress across our pipeline, which is designed to treat complement-mediated disorders of the body, brain, and eye. We generated positive data with our lead drug candidate ANX005 in Guillain-Barre Syndrome and Huntington's Disease and continued to advance our pipeline of five fit-for-purpose drug candidates.
Earlier this week, we announced promising final data from our Phase 2 trial of ANX005 in patients with Huntington's Disease that support the continued development of ANX005 for that indication. As we look ahead, we are preparing for numerous clinical data readout and new study initiation, anticipated over the course of 2022 and 2023. This is an exciting time for Annexon. I am confident in our potential to deliver game-changing medicines to patients in need.
We are conducting our annual meeting virtually via live audio webcast. Before I call
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |